Table 1.

Characteristics of the total cohort according to urinary uromodulin-to-creatinine ratio quartiles

CharacteristicsTotal, n=218 (0.8–93.7), μg/gQuartile 1, n=54 (0.8–4.1), μg/gQuartile 2, n=55 (4.2–9.9), μg/gQuartile 3, n=55 (10.0–22.8), μg/gQuartile 4, n=54 (22.9–93.7), μg/gTrend P Value
Patient
 Uromodulin/Cr, μg/ga10.0 (4.2, 22.8)2.7 (2.2, 3.4)6.7 (5.7, 7.9)15.3 (11.6, 20.1)33.3 (27.4, 41.0)
 Men, n (%)159 (72.9)43 (79.6)45 (81.8)37 (67.3)34 (63.0)0.02
 Age, yr68.1±11.368.6±11.265.8±12.569.9±9.168.1±11.90.65
 White, n (%)207 (95.0)51 (94.4)52 (94.6)53 (96.4)51 (94.4)0.89
 Diabetes, n (%)69 (31.7)15 (27.8)21 (38.2)18 (32.7)15 (27.8)0.84
 Hypertension, n (%)190 (87.2)48 (88.9)51 (92.7)47 (85.5)44 (81.5)0.15
 Heart failure, n (%)75 (34.4)25 (46.3)17 (30.9)17 (30.9)16 (29.6)0.08
 PVD, n (%)40 (18.4)6 (11.1)13 (23.6)13 (23.6)8 (14.8)0.64
 COPD, n (%)69 (31.7)14 (25.9)20 (36.4)22 (40.0)13 (24.1)0.95
 eGFR, ml/min per 1.73 m271.9±19.371.5±19.573.2±23.267.4±15.675.4±17.80.53
 Serum creatinine, mg/dl1.1±0.31.1±0.31.1±0.41.1±0.21.0±0.20.12
 Urine ACR, mg/ga16.6 (6.2, 46.5)16.7 (7.1, 30.7)15.1 (5.4, 98.1)15.8 (5.9, 36.2)18.6 (7.8, 52.7)0.48
 LVEF, %51.1±14.550.8±16.250.1±15.950.8±13.152.8±12.60.87
 Preoperative radiocontrast, n (%)150 (68.8)39 (72.2)34 (61.8)41 (74.6)36 (66.7)0.90
 Sample storage time, yr8.4±2.18.4±1.88.5±2.18.4±2.28.4±2.40.57
Surgery
 Valve only, n (%)99 (45.4)26 (48.2)22 (40.0)27 (49.1)24 (44.4)0.95
 CPB perfusion time, min115.8±47.5116.3±41.2117.8±52.1115.7±43.2113.3±53.60.60
 Nonelective surgery, n (%)142 (65.1)33 (61.1)35 (63.6)37 (67.3)37 (68.5)0.37
  • All values are expressed as n (%) or mean±SD unless noted otherwise. Uromodulin/Cr, uromodulin-to-creatinine ratio; PVD, peripheral vascular disease; COPD, chronic obstructive pulmonary disease; ACR, albumin-to-creatinine ratio; LVEF, left ventricular ejection fraction; CPB, cardiopulmonary bypass.

  • a Median (25th, 75th percentiles).